TNF-α inhibition reduces renal injury in DOCA-salt hypertensive rats

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 294, Issue 1, 2008, Pages

  Elmarakby, Ahmed A ^a   Quigley, Jeffrey E ^a   Imig, John D ^a   Pollock, Jennifer S ^a   Pollock, David M ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Blood pressure; Deoxycorticosterone acetate; Etanercept; Nuclear factor B; Renal inflammation; Tumor necrosis factor

Indexed keywords

ALBUMIN; DEOXYCORTICOSTERONE ACETATE; ETANERCEPT; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO;

ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; HYPERTENSION; KIDNEY INJURY; MALE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; TELEMETRY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; CHEMOKINE CCL2; DESOXYCORTICOSTERONE; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; HYPERTENSION; IMMUNOGLOBULIN G; INFLAMMATION; KIDNEY; KIDNEY DISEASES; MALE; MINERALOCORTICOIDS; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38148999322     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00466.2007     Document Type: Article

References (38)

1. Allcock GH, Venema RC, Pollock DM. ETA receptor blockade attenuates the hypertension but not renal dysfunction in DOCA-salt rats. Am J Physiol Regul Integr Comp Physiol 275: R245-R252, 1998.
2. Baldwin AS Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 14: 649-683, 1996.
3. Bertani T, Abbate M, Zoja C, Corna D, Perico N, Ghezzi P, Remuzzi G. Tumor necrosis factor induces glomerular damage in the rabbit. Am J Pathol 134: 419-430, 1989.
4. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC. Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 37: 781-786, 2001.
5. Callera GE, Tostes RC, Yogi A, Montezano AC, Touyz RM. Endothelin-1-induced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms. Clin Sci (Lond) 110: 243-253, 2006.
6. Chang MY, Parker E, El Nahas M, Haylor JL, Ong AC. Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease. J Am Soc Nephrol 18: 560-569, 2007.
7. Chatziantoniou C, Boffa JJ, Tharaux PL, Flamant M, Ronco P, Dussaule JC. Progression and regression in renal vascular and glomerular fibrosis. Int J Exp Pathol 85: 1-11, 2004.
8. Elmarakby AA, Morsing P, Pollock JS, Pollock DM. Omapatrilat increases renal endothelin in deoxycorticosterone acetate-salt hypertensive rats. Vascul Pharmacol 40: 253-259, 2003.
9. Elmarakby AA, Quigley JE, Pollock DM, Imig JD. Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension 47: 557-562, 2006.
10. Francis J, Beltz T, Johnson AK, Felder RB. Mineralocorticoids act centrally to regulate blood-borne tumor necrosis factor-α in normal rats. Am J Physiol Regul Integr Comp Physiol 285: R1402-R1409, 2003.
11. Goffe B, Cather JC. Etanercept: an overview. J Am Acad Dermatol 49: S105-S111, 2003.
12. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 32: 24-34, 2002.
13. Hasegawa G, Nakano K, Sawada M, Uno K, Shibayama Y, Ienaga K, Kondo M. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 40: 1007-1012, 1991.
14. Higuchi Y, Otsu K, Nishida K, Hirotani S, Nakayama H, Yamaguchi O, Matsumura Y, Ueno H, Tada M, Hori M. Involvement of reactive oxygen species-mediated NF-κB activation in TNF-α-induced cardiomyocyte hypertrophy. J Mol Cell Cardiol 34: 233-240, 2002.
15. Hruby ZW, Shirota K, Jothy S, Lowry RP. Antiserum against tumor necrosis factor-α and a protease inhibitor reduce immune glomerular injury. Kidney Int 40: 43-45, 1991.
16. Kagitani S, Ueno H, Hirade S, Takahashi T, Takata M, Inoue H. Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats. J Hypertens 22: 1007-1115, 2004.
17. LaMarca BB, Cockrell K, Sullivan E, Bennett W, Granger JP. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension 46: 82-86, 2005.
18. Little MA, Bhangal G, Smyth CL, Nakada MT, Cook HT, Nourshargh S, Pusey CD. Therapeutic effect of anti-TNF-α antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol 17: 160-169, 2006.
19. Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V, Gottlieb AB. Differential expression of phosphorylated NF-κB/RelA in normal and psoriatic epidermis and downregulation of NF-κB in response to treatment with etanercept. J Invest Dermatol 124: 1275-1283, 2005.
20. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501, 2001.
21. Marsden PA, Brenner BM. Transcriptional regulation of the endothelin-1 gene by TNF-α. Am J Physiol Cell Physiol 262: C854-C861, 1992.
22. Martin T, Cardarelli PM, Parry GC, Felts KA, Cobb RR. Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action of NF-κB and AP-1. Eur J Immunol 27: 1091-1097, 1997.
23. Matsumura Y, Hashimoto N, Taira S, Kuro T, Kitano R, Ohkita M, Opgenorth TJ, Takaoka M. Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats. Hypertension 33: 759-765, 1999.
24. Muller DN, Shagdarsuren E, Park JK, Dechend R, Mervaala E, Hampich F, Fiebeler A, Ju X, Finckenberg P, Theuer J, Viedt C, Kreuzer J, Heidecke H, Haller H, Zenke M, Luft FC. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol 161: 1679-1693, 2002.
25. Navarro JF, Milena FJ, Mora C, Leon C, Claverie F, Flores C, Garcia J. Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int 99: S98-S102, 2005.
26. Navarro JF, Mora-Fernandez C. The role of TNF-α in diabetic nephropathy: pathogenic and therapeutic implications. Cytokine Growth Factor Rev 17: 441-450, 2006.
27. Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Tomobe Y, Yamaguchi I. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 43: 1481-1488, 2004.
28. Oishi T, Ogura T, Yamauchi T, Harada K, Ota Z. Effect of renin-angiotensin inhibition on glomerular injuries in DOCA-salt hypertensive rats. Regul Pept 62: 89-95, 1996.
29. Pollock DM, Pollock JS. Evidence for endothelin involvement in the response to high salt. Am J Physiol Renal Physiol 281: F144-F150, 2001.
30. Pollock DM, Rekito A. Hypertensive response to chronic NO synthase inhibition is different in Sprague-Dawley rats from two suppliers. Am J Physiol Regul Integr Comp Physiol 275: R1719-R1723, 1998.
31. Pu Q, Amiri F, Gannon P, Schiffrin EL. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats. J Hypertens 23: 401-409, 2005.
32. Rodriguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Mezzano S, Vaziri ND. Early and sustained inhibition of nuclear factor-kappaB prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther 315: 51-57, 2005.
33. Rodriguez-Iturbe B, Quiroz Y, Ferrebuz A, Parra G, Vaziri ND. Evolution of renal interstitial inflammation and NF-κB activation in spontaneously hypertensive rats. Am J Nephrol 24: 587-594, 2004.
34. Schiffrin EL. Vascular endothelin in hypertension. Vascul Pharmacol 43: 19-29, 2005.
35. Schneider MP, Boesen EI, Pollock DM. Contrasting actions of endothelin ETA and ETB receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 47: 731-759, 2007.
36. + channel and NFκB activity in corneal epithelial cells. Exp Cell Res 311: 39-48, 2005.
37. Yamaoka S, Courtois G, Bessia C, Whiteside ST, Weil R, Agou F, Kirk HE, Kay RJ, Israel A. Complementation cloning of NEMO, a component of the IκB kinase complex essential for NF-κB activation. Cell 7: 1231-1240, 1998.
38. Zandi E, Chen Y, Karin M. Direct phosphorylation of IκB by IKKα and IKKβ: discrimination between free and NF-κB-bound substrate. Science 281: 1360-1363, 1998.